NewsBenzingaTakeda Pharmaceutical Co aumenta la guidance dell’EPS core per l’esercizio 2026 da 472 JPY a 482 JPY; aumenta la guidance dei ricavi per l’esercizio 2026 da 4.640 miliardi di JPY a 4.700 miliardi di JPY Takeda Pharmaceutical Co aumenta la guidance dell’EPS core per l’esercizio 2026 da 472 JPY a 482 JPY; aumenta la guidance dei ricavi per l’esercizio 2026 da 4.640 miliardi di JPY a 4.700 miliardi di JPY Benzinga 2026.10.29 07:57 (GMT+0) Open on Benzinga Other news Key Overnight and Morning News (Nov 17 – Nov 18) Bitcoin, Ethereum Dip, While XRP, Dogecoin Gain as US Launches 'Self-Defense' Strikes Against Iran: Analyst Asks BTC Investors to 'Endure' Next 2 Months of Pain Global robotics company Genesis AI closes $500M Series A at $3.5B post-money valuation Alphabet's AI Drug Discovery Firm Isomorphic Labs Completes $5B Series C Funding, Co-Led by Sequoia Capital and Others Bitcoin miner MARA continues selling, offloading another $121 million in BTC over the past 8 days Jeff Bezos Warns Outsider CEO Replacing Jensen Huang Faces ‘Vanishingly Small Chance of Succeeding’ at Nvidia: ‘Too Complicated’
Bitcoin, Ethereum Dip, While XRP, Dogecoin Gain as US Launches 'Self-Defense' Strikes Against Iran: Analyst Asks BTC Investors to 'Endure' Next 2 Months of Pain
Alphabet's AI Drug Discovery Firm Isomorphic Labs Completes $5B Series C Funding, Co-Led by Sequoia Capital and Others
Jeff Bezos Warns Outsider CEO Replacing Jensen Huang Faces ‘Vanishingly Small Chance of Succeeding’ at Nvidia: ‘Too Complicated’